X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs WOCKHARDT LTD. - Comparison Results

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA WOCKHARDT LTD. AJANTA PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 19.9 -20.8 - View Chart
P/BV x 4.7 2.1 222.4% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 AJANTA PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
WOCKHARDT LTD.
Mar-18
AJANTA PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1,8181,012 179.6%   
Low Rs1,106532 208.1%   
Sales per share (Unadj.) Rs239.5355.9 67.3%  
Earnings per share (Unadj.) Rs52.8-60.3 -87.6%  
Cash flow per share (Unadj.) Rs59.5-46.8 -127.3%  
Dividends per share (Unadj.) Rs00.01 0.0%  
Dividend yield (eoy) %00 0.0%  
Book value per share (Unadj.) Rs230.0257.8 89.2%  
Shares outstanding (eoy) m88.77110.63 80.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.12.2 281.5%   
Avg P/E ratio x27.7-12.8 -216.3%  
P/CF ratio (eoy) x24.6-16.5 -148.9%  
Price / Book Value ratio x6.43.0 212.4%  
Dividend payout %00 0.0%   
Avg Mkt Cap Rs m129,78285,379 152.0%   
No. of employees `0006.86.3 108.7%   
Total wages/salary Rs m3,7659,371 40.2%   
Avg. sales/employee Rs Th3,128.46,295.0 49.7%   
Avg. wages/employee Rs Th554.01,498.3 37.0%   
Avg. net profit/employee Rs Th689.7-1,066.3 -64.7%   
INCOME DATA
Net Sales Rs m21,25839,369 54.0%  
Other income Rs m2421,202 20.1%   
Total revenues Rs m21,49940,571 53.0%   
Gross profit Rs m6,58418 35,977.6%  
Depreciation Rs m5961,495 39.9%   
Interest Rs m42,555 0.2%   
Profit before tax Rs m6,226-2,830 -220.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m1,539257 598.9%   
Profit after tax Rs m4,686-6,669 -70.3%  
Gross profit margin %31.00 66,630.4%  
Effective tax rate %24.7-9.1 -272.2%   
Net profit margin %22.0-16.9 -130.2%  
BALANCE SHEET DATA
Current assets Rs m12,23633,796 36.2%   
Current liabilities Rs m3,46126,917 12.9%   
Net working cap to sales %41.317.5 236.3%  
Current ratio x3.51.3 281.6%  
Inventory Days Days6079 75.9%  
Debtors Days Days8489 94.7%  
Net fixed assets Rs m11,14039,664 28.1%   
Share capital Rs m177553 32.0%   
"Free" reserves Rs m20,23727,968 72.4%   
Net worth Rs m20,41428,522 71.6%   
Long term debt Rs m1021,731 0.0%   
Total assets Rs m24,48681,620 30.0%  
Interest coverage x1,519.4-0.1 -1,413,160.7%   
Debt to equity ratio x00.8 0.1%  
Sales to assets ratio x0.90.5 180.0%   
Return on assets %19.2-5.0 -380.1%  
Return on equity %23.0-23.4 -98.2%  
Return on capital %30.5-7.7 -397.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,6679,807 119.0%   
Fx outflow Rs m1,6161,789 90.3%   
Net fx Rs m10,0528,019 125.4%   
CASH FLOW
From Operations Rs m2,854684 417.0%  
From Investments Rs m-2,6046,302 -41.3%  
From Financial Activity Rs m-2-7,695 0.0%  
Net Cashflow Rs m248-664 -37.4%  

Share Holding

Indian Promoters % 73.8 74.5 99.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 2.3 67.4%  
FIIs % 7.6 7.7 98.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 17.0 15.4 110.4%  
Shareholders   20,968 67,757 30.9%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   BIOCON LTD  GLENMARK PHARMA  AUROBINDO PHARMA  PANACEA BIOTECH  FDC LTD.  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

GLENMARK PHARMA Plunges by 5%; BSE HEALTHCARE Index Down 2.7% (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

GLENMARK PHARMA share price has plunged by 5% and its current market price is Rs 658. The BSE HEALTHCARE is down by 2.7%. The top gainers in the BSE HEALTHCARE Index are IPCA LABS (up 1.3%) and J.B.CHEMICALS (up 1.1%). The top losers are GLENMARK PHARMA (down 5.0%) and PFIZER (down 5.9%).

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Sep 24, 2018 03:37 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - GLENMARK PHARMA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS